



REVOLUTIONIZE YOUR DRUG DISCOVERY

[WWW.HELIGENICS.COM](http://WWW.HELIGENICS.COM)

# About Us

- **Heligenics' proven breakthroughs in biotechnology power our GigaAssay™ to deliver high-quality biologic leads – at accelerated 4x speed!**
- **Our GigaAssay generates a MEGA-MAP™ activity and variant landscape**
- **Outpace the competition – Heligenics supercharges biologics discovery that is scalable at a significantly lower cost**

# Tackling Obesity: A Massive Opportunity

- **650+ million people affected worldwide**
- **Current clinical approaches and their limitations**
  - GLP-1 analogs & incretins (types of hormones), lipase inhibitors, appetite suppressants
  - **Limited potency** – requires increased dosing
  - **Immune response** reduces effectiveness
  - Nausea, diarrhea, and vomiting **drive patients away**
- **Challenges in new biologic drug development**
  - **High costs and long timelines** limit pre-clinical development
  - **Slow, tedious methods** are choking innovation and stalling lead discovery

# Incretin Tri-agonist<sup>1</sup> Solution

## Biobetter for Obesity with Balanced Activity

**GigaAssay: proprietary technology that drives market-shifting cost savings.**

- 4X faster
- 90%+ success in validation of lead<sup>2</sup> generation

Market Opportunity	Heligenics Solutions
<b>Increase potency</b>	Rapidly pinpoint potent biologics from 100k+ leads to reduce dosing and side effects
<b>Balanced activity</b>	Customized leads with desired activity across three different receptors
<b>Improved stability</b>	Discover stable leads that reduce dosing – no guesswork
<b>Oral forms</b>	Unlock oral delivery with innovative molecular tweaks and natural modifications
<b>Customized biologics</b>	MEGA-Map landscapes reveal full variant activity 4x faster than conventional single-track technology

<sup>1</sup>activation of three different receptors

<sup>2</sup>prioritized drug candidates

# Our GigaAssay Technology for Discovery of Incretin Tri-agonist Drug Leads

Our patented GigaAssay rapidly screens >100k incretin tri-agonist variants across multiple targets for precise, highly impactful results

- **Breakthrough efficiency: lower costs, faster launch**
- **Discovery and lead verification 4x faster than conventional methods**
  - Less than one year with GigaAssay vs US average of 4.5 years
  - Rapid asset validation: *A single GigaAssay will deliver up to 50 actionable leads in <1 year*
- **Tailored assays drive 90%+ projected clinical trial success**
- **GigaAssay accelerates lead validation with vast libraries and MEGA-Map landscapes**

# How? – With the GigaAssay


## 100k's of leads tested in human cells - *simultaneously*

>100k different incretin leads simultaneously

Cell-based GigaAssay measures bioactivity

Visualize GigaAssay data output for bioactivity across multiple targets

Purify, verify, patent balanced activity leads for clinical testing





# THANK YOU

---

**Dr. Martin Schiller**  
**[mschiller@heligenics.com](mailto:mschiller@heligenics.com)**

**Heligenics Inc.**  
**10530 Discovery Drive**  
**Las Vegas, NV 89135**  
**[www.heligenics.com](http://www.heligenics.com)**

